Serum and bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis. 1998

T Takahashi, and M Munakata, and I Suzuki, and Y Kawakami
First Department of Medicine, School of Medicine, Hokkaido University, Sapporo, Japan.

Pulmonary alveolar proteinosis (PAP) is a disease characterized by the filling of alveolar spaces with periodic acid-Schiff-positive proteinaceous material and by the hypertrophy of type II pneumocytes in the alveolar interstitium. To examine if KL-6, a mucinlike glycoprotein, is useful for the diagnosis of PAP and the estimation of its activity, serum KL-6 levels in patients with PAP were measured by an enzyme-linked immunosorbent assay and compared with those of patients with other lung diseases. Furthermore, to estimate the origin of KL-6 in some patients, measurements of KL-6 levels in bronchoalveolar lavage (BAL) fluid and immunohistochemical staining of the lung tissues with a monoclonal antibody to KL-6 antigen were performed. Serum KL-6 levels in patients with PAP were extremely high and were significantly higher than those in patients with interstitial lung diseases in which elevation of serum KL-6 has been recognized. BAL-fluid KL-6 levels in patients with PAP were higher than serum levels. Both serum and BAL-fluid KL-6 levels in patients with PAP correlated well with the disease activity. Immunohistochemically, positive staining was observed in proliferating type II pneumocytes. These results suggest the usefulness of KL-6 measurement in the diagnosis and estimation of disease activity of PAP.

UI MeSH Term Description Entries
D006984 Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA). Hypertrophies
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009077 Mucins High molecular weight mucoproteins that protect the surface of EPITHELIAL CELLS by providing a barrier to particulate matter and microorganisms. Membrane-anchored mucins may have additional roles concerned with protein interactions at the cell surface. Mucin
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010503 Periodic Acid-Schiff Reaction A histochemical technique for staining carbohydrates. It is based on PERIODIC ACID oxidation of a substance containing adjacent hydroxyl groups. The resulting aldehydes react with Schiff reagent to form a colored product. PAS Reaction,PAS Reactions,Periodic Acid Schiff Reaction,Periodic Acid-Schiff Reactions,Reaction, PAS,Reaction, Periodic Acid-Schiff,Reactions, PAS,Reactions, Periodic Acid-Schiff
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D011649 Pulmonary Alveolar Proteinosis A PULMONARY ALVEOLI-filling disease, characterized by dense phospholipoproteinaceous deposits in the alveoli, cough, and DYSPNEA. This disease is often related to, congenital or acquired, impaired processing of PULMONARY SURFACTANTS by alveolar macrophages, a process dependent on GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR. Alveolar Proteinoses, Pulmonary,Alveolar Proteinosis, Pulmonary,Proteinoses, Pulmonary Alveolar,Proteinosis, Pulmonary Alveolar,Pulmonary Alveolar Proteinoses

Related Publications

T Takahashi, and M Munakata, and I Suzuki, and Y Kawakami
April 2016, Orphanet journal of rare diseases,
T Takahashi, and M Munakata, and I Suzuki, and Y Kawakami
February 2017, Journal of thoracic disease,
T Takahashi, and M Munakata, and I Suzuki, and Y Kawakami
April 2013, Orphanet journal of rare diseases,
T Takahashi, and M Munakata, and I Suzuki, and Y Kawakami
September 1998, Thorax,
T Takahashi, and M Munakata, and I Suzuki, and Y Kawakami
December 1983, Inflammation,
T Takahashi, and M Munakata, and I Suzuki, and Y Kawakami
February 2015, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases,
T Takahashi, and M Munakata, and I Suzuki, and Y Kawakami
May 1995, The European respiratory journal,
T Takahashi, and M Munakata, and I Suzuki, and Y Kawakami
April 2006, The Tohoku journal of experimental medicine,
T Takahashi, and M Munakata, and I Suzuki, and Y Kawakami
June 1986, Zhonghua jie he he hu xi xi ji bing za zhi = Chinese journal of tuberculosis and respiratory diseases,
T Takahashi, and M Munakata, and I Suzuki, and Y Kawakami
January 1999, Pediatric hematology and oncology,
Copied contents to your clipboard!